A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers

This is a research study to determine how safe and effective a new treatment, called IMC-F106C, is for treating advanced cancers. This study is the first time the study drug is being tested in people. IMC-F106C has been developed to treat cancer by activating the body’s own immune system to fight the tumor. The study drug has 2 parts. The first part, called a “T cell receptor”, sticks very tightly to tumor cells that make markers called “HLA-A*02:01” and “PRAME”. The second part, called “anti-CD3 scFv”, sticks to a T cell (a type of white blood cell that helps protect your body against disease). IMC F106C makes the T cell stick to the cancer cell, which then sends a signal to attack the tumor.

Are you Eligible? (Inclusion Criteria)

• Are you at least 18 years of age?
• Are you able to perform every day tasks independently?
• Have you been diagnosed with melanoma, ovarian carcinoma, uterine carcinoma, NSCLC, SCLC, urothelial carcinoma, or breast cancer?